TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19853906
Drug: Liraglutide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (all doses)
Study: 12450642
Drug: Hydrocortisone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (50 mg orally)
Study: 6352659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cephalothin, carbenicillin and gentamicin
Study: 31302943
Drug: Oral Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tranexamic Acid (TA) 1,500 mg daily for 6 weeks
Study: 9387206
Drug: Aspirin, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 100 mg daily
Study: 20150175
Drug: Magnetic-activated cell
Normalized name: Activated natural killer cell therapy
DrugBank: Activated natural killer cell therapy (DB17172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic-activated cell sorting (MACS) for sperm preparation (D + M)
Study: 15465628
Drug: Pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment with guanine nucleotides (GTP)
Study: 9637638
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil at a dosage of 0.1 microg kg(‐1) x min(‐1) until skin closure
Study: 3288460
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg pirenzepine
Study: 2886245
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine
Study: 2904218
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine plus 50 mg pirenzepine
Study: 21756812
Drug: Milrinone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (5 mg diluted in 5 ml normal saline inhaled every 8 hours for two days pre-operation)
Study: 21756812
Drug: Control (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (10 ml normal saline inhaled)
Study: 19637941
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg twice/day
Study: 19637941
Drug: Metoprolol succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol succinate (various doses: 25, 50, 100, 200 mg once/day)
Study: 19637941
Drug: Carvedilol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (various doses: 3.125, 6.25, 12.5, 25 mg twice/day)
Study: 10357747
Drug: 60 or
Normalized name: QM-260 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 or 120 mg Fe plus 3.5 mg folic acid weekly for 22 weeks
Study: 7012343
Drug: Group counseling
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group counseling and education (12 weekly sessions)
Study: 29401177
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg oral)
Study: 29418049
Drug: SBIRT program
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBIRT program (brief motivational intervention on alcohol use and referral to specialized treatment)
Study: 22663011
Drug: trametinib (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: trametinib (2 mg orally once daily)
Study: 22663011
Drug: chemotherapy (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy (intravenous dacarbazine 1000 mg/m² or paclitaxel 175 mg/m² every 3 weeks)
Study: 15854844
Drug: Estimation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estimation of lung tumor volumes during radiotherapy treatment planning.
Study: 11248608
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER 4 mg once daily
Study: 2541193
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg by pressurized aerosol)
Study: 19037613
Drug: Lomotil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomotil (5 mg diphenoxylate hydrochloride/0.05 mg atropine sulfate)
Study: 19037613
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL water (control group)
Study: 2502837
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg, single oral dose)
Study: 2502837
Drug: Amoxycillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (3 g) and Probenecid (1 g, single oral dose)
Study: 1269432
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion at 20 mug/min in group I
Study: 1269432
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion at 20 mug/min in group II
Study: 1269432
Drug: Nitroprusside infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroprusside infusion in group I
Study: 30797492
Drug: GC +
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC + N (necitumumab 800 mg on days 1 and 8 of a 3-week cycle, gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Study: 30797492
Drug: GC (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GC (gemcitabine 1250 mg/m2 on days 1 and 8, cisplatin 75 mg/m2 on day 1)
Study: 25297337
Drug: Adenosine/verapamil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine/verapamil (40 mg orally after converting to sinus rhythm)
Study: 25297337
Drug: Adenosine only
Normalized name: Adenosine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine only (6 mg rapid bolus intravenous injection followed by two repeated doses of 12 mg if necessary)
Study: 29793565
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal thermo-sensitive gel (TLTG)
Study: 25795459
Drug: Pre-operative occupational
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative occupational therapy intervention (home visit by an occupational therapist)
Study: 26300269
Drug: Postoperative SSA
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative SSA treatment
Study: 26300269
Drug: Postoperative pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Postoperative pegvisomant treatment
Study: 23609368
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (200 µg)
Study: 16751162
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intrathecal morphine)
Study: 15587094
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.3 mg/kg)
Study: 19021008
Drug: 0.5mg/kg ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg/kg ketamine by intravenous route before induction
Study: 19021008
Drug: 0.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg 0.2% ropivacaine caudally and 2ml normal saline intravenously
Study: 19021008
Drug: 0.7 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg 0.2% ropivacaine caudally and 0.5mg/kg ketamine by intravenous route
Study: 16640101
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy (peg-IFN-alpha2a and 3TC)
Study: 11050695
Drug: Onion-olive-oil maceration
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion-olive-oil maceration capsule formulation
Study: 8351023
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 to 150 mg/d
Study: 3717537
Drug: Morphine orally
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine orally and scopolamine transdermally
Study: 3717537
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine and scopolamine
Study: 22775130
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of rumination in response to unpleasant daily events
Study: 22775130
Drug: Lower use
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower use of rumination in response to unpleasant daily events
Study: 9758242
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg daily
Study: 18725220
Drug: Sibutramine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (10 or 15 mg)
Study: 2662354
Drug: Praziquantel 60
Normalized name: praziquantel 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 60 mg daily dose
Study: 2662354
Drug: Praziquantel 75
Normalized name: METRONIDAZOLE 250 mg in 2 g / PRAZIQUANTEL 75 mg in 2 g TOPICAL POWDER [API General Cure]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 75 mg daily dose in 15-29 year old patients
Study: 29214645
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg.kg‐1
Study: 29214645
Drug: Neostigmine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 40 μg.kg‐1 and glycopyrrolate 400 μg
Study: 20800380
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with daily 18 fractions (Arm 2)
Study: 20800380
Drug: Prophylactic cranial
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic cranial irradiation (PCI) to a total dose of 36 Gy with twice-daily 24 fractions (Arm 3)
Study: 17124621
Drug: escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 20 mg + pindolol (5-HT(1a) antagonist) 10 mg
Study: 17124621
Drug: escitalopram 20
Normalized name: escitalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 20 mg + ketanserin (5-HT(2a) antagonist) 50 mg
Study: 15134388
Drug: Stabilized oral
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilized oral NADH (10 mg/day)
Study: 11772296
Drug: Tissue factor
Normalized name: Tissue factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue factor pathway inhibitor (TFPI)
Study: 9619701
Drug: Lubeluzole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubeluzole 7.5 mg over 1 h followed by 10 mg/day for up to 5 days
Study: 7930256
Drug: Enalaprilat (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.6 micrograms/min per 100 ml tissue volume)
Study: 7930256
Drug: NG‐monomethyl‐L‐arginine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: NG‐monomethyl‐L‐arginine (n = 10)
Study: 3086359
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (8 mg in 1 min followed by 12 mg in 3 h)
Study: 3086359
Drug: Testosterone undecanoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone undecanoate, 40 mg three times a day by mouth
Study: 22488002
Drug: Soybean oil-based
Normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oil-based parenteral nutrition (Intralipid)
Study: 22488002
Drug: Olive oil-based
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil-based parenteral nutrition (ClinOleic)
Study: 21040626
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 97 mg L-theanine and 40 mg caffeine
Study: 18349061
Drug: Daily PTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily PTH
Study: 17703634
Drug: Telmisartan/Hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Hydrochlorothiazide combination
Study: 25651363
Drug: ZS-9 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS-9 3 g three times daily for 2 days
Study: 25651363
Drug: ZS-9 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS-9 10 g three times daily for 2 days
Study: 26011677
Drug: ZS-9 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZS-9 10 g
Study: 11131448
Drug: Etidronate 400
Normalized name: etidronate 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate 400 mg/day for 14 days every 3 months for at least 1 year with supplemental calcium
Study: 8886085
Drug: Hyalectin 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalectin 20 mg
Study: 30306831
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for 8 weeks
Study: 2708190
Drug: Dichloroacetate infusion
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate infusion
Study: 31767215
Drug: internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: internet delivered cognitive behaviour therapy (iCBT) for eight weeks, five sessions (n=150)
Study: 16442406
Drug: Intravenous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous low-dose vitamin K
Study: 14872180
Drug: Cold-adapted trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted trivalent intranasal influenza virus vaccine (CAIV)
Study: 7995183
Drug: Max-EPA (triglyceride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Max-EPA (triglyceride preparation)
Study: 2741263
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment only
Study: 2741263
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment plus 5-fluorouracil 5% ointment
Study: 2741263
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment and adjuvant 5-fluorouracil 2% painting
Study: 22219315
Drug: 6 μg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 μg reduced-dose seasonal trivalent influenza vaccine
Study: 22219315
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg conventional seasonal trivalent influenza vaccine
Study: 7570406
Drug: Asthma self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma self-management programme (four 2.5 hour education sessions at weekly intervals)
Study: 466952
Drug: Glucagon (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (2 mg intravenous)
Study: 27607861
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (saline)
Study: 26789096
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (250 mg)
Study: 26789096
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid supplementation (500 mg)
Study: 19996931
Drug: High-stringency CD8-depleted
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-stringency CD8-depleted DLI (starting dose: 1 x 10(6) CD4 cells/kg for unrelated, 3 x 10(6) CD4 cells/kg for related)
Study: 16027402
Drug: Pentosan polysulfate
Normalized name: Pentosan polysulfate
DrugBank: Pentosan polysulfate (DB00686)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentosan polysulfate sodium 100 mg every 8 hours for 7 days
Study: 12412994
Drug: UDCA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA plus suplatast tosilate (300 mg/day tid)
Study: 12412994
Drug: UDCA alone
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA alone (600 mg/day tid)
Study: 30650259
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg)
Study: 23669513
Drug: Early limited
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early limited formula (10 mL formula by syringe after each breastfeeding, discontinued when mature milk production began)
Study: 20972878
Drug: Low-intensity resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity resistance training (LSR) at 50% of one repetition maximum for 10 weeks, performed twice a week with five sets of ten repetitions and 30 seconds inter-set rest period
Study: 18984831
Drug: Very early
Normalized name: Primula veris extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very early mobilization and task-oriented physical therapy
Study: 12620953
Drug: Diltiazem (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (2 micro g x kg(‐1) x min(‐1))
Study: 12620953
Drug: Dopamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (2.5 micro g x kg(‐1) x min(‐1))
Study: 7473239
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of BCAA (6 g l-1)
Study: 7473239
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of BCAA (18 g l-1)
Study: 29999208
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the tibia bone for 100 seconds prior to PPCI and at 24 and 72 hours post-PPCI.
Study: 26330561
Drug: Early home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early home-based group education on renal replacement therapy (RRT) options
Study: 22464760
Drug: 17β‐estradiol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17β‐estradiol (4 mg/d)
Study: 18356842
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day CLA (50:50 cis-9, trans-11:trans-10, cis-12) and 3 g/day n-3 LC-PUFA
Study: 18356842
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day control fat
Study: 12666963
Drug: Metronidazole 25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 25% dental gel (ELYZOL DENTAL GEL) applied on day 0 and day 7
Study: 12666963
Drug: Scaling adjunctive
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling adjunctive to metronidazole 25%
Study: 17852789
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of clopidogrel until 30 days after OPCAB surgery
Study: 15681270
Drug: Spinal Manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulative Therapy (MT)
Study: 11943636
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (15 mg iron/day) for 3 months
Study: 11943636
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (15 mg iron/day) for 6 months
Study: 11943636
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (15 mg iron/week) for 6 months
Study: 8097332
Drug: Guanfacine (GUA)
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine (GUA) 1.5 mg IV
Study: 3800343
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g mezlocillin every 8 h
Study: 30138389
Drug: Antithrombotic medications
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic medications (including aspirin-dipyridamole plus clopidogrel, rivaroxaban plus aspirin, warfarin plus aspirin, warfarin plus aspirin and clopidogrel)
Study: 30138389
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus aspirin and clopidogrel
Study: 30138389
Drug: Dabigatran monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran monotherapy
Study: 30138389
Drug: Dabigatran plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran plus aspirin
Study: 30138389
Drug: Users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Users of antithrombotic medication
Study: 21709087
Drug: Dihydroartemisinin‐piperaquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin‐piperaquine with 200 ml milk containing 6.4 g fat (n = 15)
Study: 11111997
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin (UW) preservation solution (n = 20)
Study: 11111997
Drug: Celsior preservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celsior preservation solution (n = 21)
Study: 3255485
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control group)
Study: 26886017
Drug: Pegfilgrastim administered
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administered the same day as chemotherapy
Study: 26886017
Drug: Pegfilgrastim administered
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim administered the next day after chemotherapy
Study: 24128381
Drug: Smoking-cessation treatment
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smoking-cessation treatment (SCT) including weekly individual counseling, extended-release bupropion (300 mg/day), nicotine inhaler, and contingency management for smoking abstinence
Study: 15782318
Drug: 10 ppm
Normalized name: Glycerin 1.0 g in 25 mL TOPICAL CREAM [EGF Crystal 10 ppm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ppm inhaled nitric oxide (iNO)
Study: 12424485
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g dipyrone in 10 ml saline
Study: 12424485
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous injection of 10 ml saline)
Study: 9495568
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (0.05 g/day) for six months
Study: 9495568
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (0.05 g/day) + Medroxyprogesterone acetate (MPA; 10 mg/day, per orally for the last ten days)
Study: 24417987
Drug: aranidipine 5-20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aranidipine 5-20 mg/d
Study: 24417987
Drug: retard-released felodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: retard-released felodipine 5-10 mg/d